Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: A proof of principle.
Sanchez Gil J, Dubois M, Neirinckx V, Lombard A, Coppieters N, D'Arrigo P, Isci D, Aldenhoff T, Brouwers B, Lassence C, Rogister B, Lebrun M, Sadzot-Delvaux C.
Sanchez Gil J, et al. Among authors: d arrigo p.
Mol Ther Oncolytics. 2022 Jun 6;26:35-48. doi: 10.1016/j.omto.2022.06.002. eCollection 2022 Sep 15.
Mol Ther Oncolytics. 2022.
PMID: 35784400
Free PMC article.